Nivolumab Response Probability by Tumor Biomarkers

Estimate nivolumab (PD-1 inhibitor) response probability using PD-L1 TPS/CPS, tumor mutational burden (TMB), MSI-H status, and tumor type for treatment decision support.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Estimate nivolumab (PD-1 inhibitor) response probability using PD-L1 TPS/CPS, tumor mutational burden (TMB), MSI-H status, and tumor type for treatment decision support

Each component has a specific meaning:

  • PD-L1 TPS/CPS — The pd-l1 tps/cps recorded for the scenario being assessed.
  • Tumor mutational burden — The tumor mutational burden recorded for the scenario being assessed.
  • MSI-H status — The msi-h status recorded for the scenario being assessed.
  • Tumor type — The tumor type recorded for the scenario being assessed.

Note: Interpret the nivolumab response probability result against the thresholds and context described above.

How to Use

Enter the PD-L1 TPS/CPS, tumor mutational burden, MSI-H status, tumor type for the scenario you are assessing. Estimate nivolumab (PD-1 inhibitor) response probability using PD-L1 TPS/CPS, tumor mutational burden (TMB), MSI-H status, and tumor type for treatment decision support. Use the nivolumab response probability result to inform your calculation.

Related Calculators

Pembrolizumab irAE Score

Medical Long-tail

Frequently Asked Questions